Adrián LLerena - Concepedia

Author

Adrián LLerena

Also Known As

A LLERENA, A LLerena, A Llerena, A Llerena (19708369), A. LLerena, A. Llerena, Adrian LLerena, Adrian Llerena, Adrin Llerena, AdriÁN Llerena

303

Publications

8.6K

Citations

H-Index

130

Concepts

All Affiliations

Universidad de Extremadura Centro de Investigación Biomédica en Red de Salud Mental Karolinska Institutet Instituto de Salud Carlos III University of Beira Interior

About

Adrián LLerena is an author at Universidad de Extremadura specializing in medicine, pharmacology, and psychiatry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	59	3.1K
2	Social Sciences	12	13	1.4K
3	Public Health	9	9	286
4	Natural Sciences	4	4	120
5	Engineering	2	2	71

Adrián LLerena

123

Publications

6.3K

Citations

H-Index

Page 1

	Year	Citations
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2D6</i> and <i>CYP2C19</i> Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors J K Hicks, JR Bishop, Katrin Sangkuhl, Clinical Pharmacology & Therapeutics PsychopharmacologyPharmacotherapySocial SciencesMolecular PharmacologyClinical Trials	2015	946
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Leif Bertilsson, JA Carrillo, M-L Dahl, British Journal of Clinical Pharmacology	1994	306
An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels José de León, Georgios Schoretsanitis, Robert L. Smith, Pharmacopsychiatry	2021	234
Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the <i>CYP2C9</i> genotype Ümit Yaşar, Cecilia Forslund‐Bergengren, Gunnel Tybring, Clinical Pharmacology & Therapeutics	2002	182
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2C9</i> and <i>HLA‐B</i> Genotypes and Phenytoin Dosing: 2020 Update Jason H. Karnes, Allan E. Rettie, Andrew A. Somogyi, Clinical Pharmacology & Therapeutics Toxic Epidermal NecrolysisTherapeutic Drug MonitoringTranslational PharmacologyClinical TherapeuticAntiepileptic Drug	2020	163
Haloperidol Disposition Is Dependent on Debrisoquine Hydroxylation Phenotype Adrián LLerena, Christina Alm, Marja‐Liisa Dahl, Therapeutic Drug Monitoring	1992	156
Relationship between personality and debrisoquine hydroxylation capacity Adrián LLerena, Gunnar Edman, J. Cobaleda, Acta Psychiatrica Scandinavica	1993	146
Pharmacogenomics Education: International Society of Pharmacogenomics Recommendations for Medical, Pharmaceutical, and Health Schools Deans of Education David Gurwitz, Jeantine E. Lunshof, George Dedoussis, The Pharmacogenomics Journal Systems PharmacologyPharmacogenomics RecommendationsPharmacologyPharmacogenomicsPharmacogenetics	2005	126
Disposition of clozapine in man: lack of association with debrisoquine and S‐mephenytoin hydroxylation polymorphisms. M-L Dahl, Adrián LLerena, Ulf Bondesson, British Journal of Clinical Pharmacology	1994	106
Haloperidol Disposition Is Dependent on the Debrisoquine Hydroxylation Phenotype Adrián LLerena, Marja-Liisa Dahl, Britta Ekqvist, Therapeutic Drug Monitoring	1992	99

Page 1